<DOC>
	<DOCNO>NCT03035279</DOCNO>
	<brief_summary>This multicenter , open-label , Phase 1 study participant colorectal cancer ( CRC ) , consist Part A ( dose regimen find ) , follow Part B ( dose expansion ) . Part A ( dose regimen find ) involve dose escalation possible dose interval modification define maximum tolerate dose ( MTD ) and/or recommend Phase 2 dose ( RP2D ) schedule . Part B ( dose expansion ) enroll additional participant treat study drug dose MTD determine Part A .</brief_summary>
	<brief_title>A Study SC-006 Subjects With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Participants histologically cytologically confirm advanced metastatic unresectable colorectal cancer ( CRC ) relapse , refractory , progressive follow least 2 prior systemic regimen metastatic setting . Participants Eastern Cooperative Oncology Group ( ECOG ) 0 1 . Participants adequate hematologic , hepatic , renal function . Participants prior exposure pyrrolobenzodiazepine indolinobenzodiazepine base drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced colorectal cancer</keyword>
	<keyword>Unresectable colorectal cancer</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>